BROOKE TUTTLE: Open Payments
NPI 1871014159 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$968 in 60 payments from 18 companies in 2025. Trend: 2023 $688 · 2024 $851 · 2025 $968
Food & beverage: $968
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $208 |
| Otsuka America Pharmaceutical, Inc. | 15 | $144 |
| PFIZER INC. | 6 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $90 |
| Astellas Pharma US Inc | 3 | $69 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| Exact Sciences Corporation | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Novo Nordisk Inc | 2 | $32 |
Products named: VRAYLAR, REXULTI, CAPLYTA, PREVNAR 20, Veozah, Cologuard Collection Kit, FARXIGA, Symbravo.
Industry payments across UT — which companies pay providers there.
